Summary:
In overweight adults aged 19–65 years with BMI 25–30 kg/m² and elevated waist circumference, CKDB-322 supplementation (1.0 × 109 CFU of L. plantarum Q180 and 200 mg of P. tricornutum daily) significantly reduced body fat mass, abdominal adiposity, body weight, triglycerides, and leptin levels compared to placebo, though it was associated with no clinically significant adverse events or laboratory abnormalities.
| PICO | Description |
|---|---|
| Population | Overweight adults aged 19–65 years with a body mass index (BMI) of 25–30 kg/m² and waist circumference ≥90 cm for men or ≥85 cm for women. |
| Intervention | Daily oral supplementation with CKDB-322 containing 1.0 × 109 CFU of Lactiplantibacillus plantarum Q180 and 200 mg of Phaeodactylum tricornutum for 12 weeks. |
| Comparison | Placebo group receiving an inert supplement identical in appearance, taken daily for 12 weeks. |
| Outcome | Statistically significant reductions in body fat mass, body fat percentage (via DEXA), and abdominal fat area (via CT) were observed in the intervention group. Improvements in anthropometric measures, serum triglyceride, and leptin levels were also noted. No serious adverse effects were reported, and CKDB-322 was well tolerated. |
Source: Baek, Hyang-Im, et al. “Efficacy and Safety of CKDB-322, a Combination of Lactiplantibacillus plantarum Q180 and Phaeodactylum tricornutum, for Reducing Body Fat and Abdominal Adiposity in Overweight Adults.” Read article here.
